FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued DTG/ABC/3TC at Week 48

Clinical Care Options (CCO) commentary from Dr Darrell Tan on the dosing options for long-acting injectable cabotegravir plus rilpivirine for HIV treatment

Babafemi Taiwo, MBBS
Program Director Darrell H. S. Tan, MD, FRCPC, PhD Released: August 12, 2022

Drs. Jean Rene Anderson and William Short speak to the balancing act when considering HIV treatments during pregnancy, from Clinical Care Options (CCO)

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 12, 2022 Expired: August 11, 2023

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Expert summaries of ART treatment initiation in treatment-naive PWH, including rapid and same-day ART starts, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Released: August 4, 2022